drug · antibody
satralizumab
Phase 3updated 3mo agoby F. Hoffmann-La Roche Ltd🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for neuromyelitis optica and immune system disease and 7 investigational indications.
indications
indications
Duchenne Muscular Dystrophy
targets
IL6Ralpha/GP130
all catalysts(0)
nothing on the calendar yet
Trials studying satralizumab
- phase3A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
- phase3A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
- phase3A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
- phase3A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
- phase2A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
- phase3A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
- phase2Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)
- EP1Satralizumab in Aneurysmal Subarachnoid Hemorrhage
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 52m ago
Found something off?
comments(0)
5-min edit window · permanent after that